LYNPARZA® (olaparib) Reduced the Risk of Disease Progression or Death as First-Line Maintenance Treatment in Germline BRCA-Mutated Metastatic Pancreatic Cancer - Business Wire

LYNPARZA® (olaparib) Reduced the Risk of Disease Progression or Death as First-Line Maintenance Treatment in Germline BRCA-Mutated Metastatic Pancreatic Cancer  Business Wire

AstraZeneca and Merck's LYNPARZA Is the First PARP Inhibitor to Demonstrate Benefit in gBRCAm Metastatic Pancreatic Cancer in a Phase 3 Trial. February ...



Comments

Popular posts from this blog

“Stem cells: A possible treatment for severe respiratory failure, a COVID-19 complication - Mirage News” plus 1 more

“Evidence of cross-species filovirus transmission from bats to humans - EurekAlert” plus 2 more

“Screening for hearing loss in primary care - Contemporary Pediatrics” plus 1 more